{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:47:26Z","timestamp":1783352846889,"version":"3.54.6"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.msard.2025.106544","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T12:06:22Z","timestamp":1747915582000},"page":"106544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Navigating a paradigm shift in the treatment of CNS demyelinating diseases in a middle-income country"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8906-8027","authenticated-orcid":false,"given":"Elaine","family":"Chew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia L.","family":"Rotstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthi","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2025.106544_bib0016","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ana.26914","article-title":"Real-world healthcare cost savings and reduced relapse rate with off-label Rituximab versus disease-modifying treatments approved for relapsing-remitting multiple sclerosis: A nationwide cost-effectiveness study","volume":"95","author":"Alping","year":"2024","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106544_bib0012","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s41669-022-00363-1","article-title":"Cost-effectiveness analysis of Ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada","volume":"6","author":"Baharnoori","year":"2022","journal-title":"Pharmacoecon. Open."},{"issue":"3","key":"10.1016\/j.msard.2025.106544_bib0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106544_bib0013","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12913-016-1615-z","article-title":"The effectiveness of clinical networks in improving quality of care and patient outcomes: a systematic review of quantitative and qualitative studies","volume":"16","author":"Brown","year":"2016","journal-title":"BMC. Health Serv. Res."},{"key":"10.1016\/j.msard.2025.106544_bib0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.msard.2017.10.015","article-title":"Prevalence of neuromyelitis optica spectrum disorder in the multi-ethnic Penang Island, Malaysia, and a review of worldwide prevalence","volume":"19","author":"Hor","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2025.106544_bib0021","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMa Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106544_bib0007","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106544_bib0017","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00415-019-09676-4","article-title":"Differentiating societal costs of disability worsening in multiple sclerosis","volume":"267","author":"Ness","year":"2020","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106544_bib0006","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106544_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104581","article-title":"Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis","volume":"71","author":"Pipek","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2025.106544_bib0023","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive Neuromyelitis Optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.msard.2025.106544_bib0008","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.autrev.2006.02.001","article-title":"Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis","volume":"5","author":"Rotstein","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2025.106544_bib0015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fneur.2018.00174","article-title":"Therapeutic inertia in the new landscape of Multiple sclerosis care","volume":"9","author":"Saposnik","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106544_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106544_bib0014","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/13524585241258692","article-title":"Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model","volume":"30","author":"Smets","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106544_bib0024","unstructured":"The Multiple Sclerosis International Federation. Atlas of MS \u20133rd Edition, part 2: clinical management of multiple sclerosis around the world (April 2021)."},{"issue":"2","key":"10.1016\/j.msard.2025.106544_bib0003","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2025.106544_bib0004","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/1352458518792430","article-title":"A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia","volume":"25","author":"Viswanathan","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106544_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105555","article-title":"Multi-actor system dynamics in access to disease-modifying treatments for multiple sclerosis in Southeast Asia: A regional survey and suggestions for improvement","volume":"85","author":"Viswanathan","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"14","key":"10.1016\/j.msard.2025.106544_bib0018","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106544_bib0002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.msard.2025.106544_bib0009","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3111\/13696998.2010.525989","article-title":"Contribution of intangible costs to the economic burden of multiple sclerosis","volume":"13","author":"Wundes","year":"2010","journal-title":"J. Med. Econ."},{"issue":"22","key":"10.1016\/j.msard.2025.106544_bib0022","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2025.106544_bib0020","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s10072-021-05609-0","article-title":"Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors","volume":"43","author":"Zhang","year":"2022","journal-title":"Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500286X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500286X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T23:11:48Z","timestamp":1754003508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500286X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":24,"alternative-id":["S221103482500286X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106544","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating a paradigm shift in the treatment of CNS demyelinating diseases in a middle-income country","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106544"}}